BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34416429)

  • 1. UBCH5 Family Members Differentially Impact Stabilization of Mutant p53 via RNF128 Iso1 During Barrett's Progression to Esophageal Adenocarcinoma.
    Ray P; Nancarrow DJ; Ferrer-Torres D; Wang Z; San Martinho M; Hinton T; Wu JH; Wu A; Turgeon DK; Hammer MA; Dame MK; Lawrence TS; O'Brien PJ; Spence JR; Beer DG; Ray D
    Cell Mol Gastroenterol Hepatol; 2022; 13(1):129-149. PubMed ID: 34416429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.
    Ray D; Ray P; Ferrer-Torres D; Wang Z; Nancarrow D; Yoon HW; San Martinho M; Hinton T; Owens S; Thomas D; Jiang H; Lawrence TS; Lin J; Lagisetty K; Chang AC; Beer DG
    Gastroenterology; 2020 Feb; 158(3):583-597.e1. PubMed ID: 31715145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chaperones and Ubiquitin Ligases Balance Mutant p53 Protein Stability in Esophageal and Other Digestive Cancers.
    Martinho MS; Nancarrow DJ; Lawrence TS; Beer DG; Ray D
    Cell Mol Gastroenterol Hepatol; 2021; 11(2):449-464. PubMed ID: 33130332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.
    Stachler MD; Camarda ND; Deitrick C; Kim A; Agoston AT; Odze RD; Hornick JL; Nag A; Thorner AR; Ducar M; Noffsinger A; Lash RH; Redston M; Carter SL; Davison JM; Bass AJ
    Gastroenterology; 2018 Jul; 155(1):156-167. PubMed ID: 29608884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53-mutant clones and field effects in Barrett's esophagus.
    Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
    Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.
    Hardwick RH; Shepherd NA; Moorghen M; Newcomb PV; Alderson D
    Gut; 1994 Jun; 35(6):764-8. PubMed ID: 8020801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma.
    Moore JH; Lesser EJ; Erdody DH; Natale RB; Orringer MB; Beer DG
    Int J Cancer; 1994 Feb; 56(4):487-93. PubMed ID: 7906678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
    Feith M; Stein HJ; Mueller J; Siewert JR
    Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of p53 in Barrett's esophagus.
    Keswani RN; Noffsinger A; Waxman I; Bissonnette M
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1243-9. PubMed ID: 16835318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
    Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
    Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
    Kaz AM; Luo Y; Dzieciatkowski S; Chak A; Willis JE; Upton MP; Leidner RS; Grady WM
    Genes Chromosomes Cancer; 2012 Apr; 51(4):384-93. PubMed ID: 22170739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
    Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment.
    Hritz I; Gyorffy H; Molnar B; Lakatos G; Sipos F; Pregun I; Juhasz M; Pronai L; Schaff Z; Tulassay Z; Herszenyi L
    Pathol Oncol Res; 2009 Jun; 15(2):183-92. PubMed ID: 18752044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic profiles of Barrett's esophagus and esophageal adenocarcinoma in Japanese patients.
    Tokunaga M; Okimoto K; Akizue N; Ishikawa K; Hirotsu Y; Amemiya K; Ota M; Matsusaka K; Nishimura M; Matsushita K; Ishikawa T; Nagashima A; Shiratori W; Kaneko T; Oura H; Kanayama K; Ohta Y; Taida T; Saito K; Matsumura T; Chiba T; Mochizuki H; Arai M; Kato J; Ikeda JI; Omata M; Kato N
    Sci Rep; 2021 Sep; 11(1):17671. PubMed ID: 34480065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of p53 protein in Barrett's syndrome with malignant transformation.
    Fléjou JF; Potet F; Muzeau F; Le Pelletier F; Fékété F; Hénin D
    J Clin Pathol; 1993 Apr; 46(4):330-3. PubMed ID: 8496390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D; Fléjou JF
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation.
    Shukla S; Allam US; Ahsan A; Chen G; Krishnamurthy PM; Marsh K; Rumschlag M; Shankar S; Whitehead C; Schipper M; Basrur V; Southworth DR; Chinnaiyan AM; Rehemtulla A; Beer DG; Lawrence TS; Nyati MK; Ray D
    Neoplasia; 2014 Feb; 16(2):115-28. PubMed ID: 24709419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.